Sepsis treatment methods
View Patent ↗The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
1. A compound having the structure
wherein the dotted lines are optional double bonds;
R 1 is —OH or an ester;
R 4 in the β-configuration is —OH or an ester and R 4 in the α-configuration is —H or optionally substituted alkynyl or both R 4 together are ═O;
R 10A is halogen, —OH, ═O or an ester;
R 10C is —H, halogen, ═O, —OH or an ester;
R 10D is —OH, ═O or an ester; and
R 10 at position 5 if present is —H in the α- or β-configuration;
wherein the esters independently are a hydroxyl ester.
2. The compound of claim 1 having the structure
3. The compound of claim 2 wherein R 10A is —F.
4. The compound of claim 3 having the structure
5. The compound of claim 4 wherein R 4 in the α-configuration is alkynyl.
6. The compound of claim 4 wherein R 4 in the α-configuration is —CCH or —CCCH 3 .
7. The compound of claim 4 wherein both R 4 together are ═O.
8. The compound of claim 3 having the structure
9. The compound of claim 8 wherein R 4 in the α-configuration is alkynyl.
10. The compound of claim 8 wherein R 4 in the α-configuration is —CCH or —CCCH 3 .
11. The compound of claim 8 wherein both R 4 together are ═O.
12. The compound of claim 3 wherein the compound is 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one.